Authors: Rita Baron-Faust,Jill Buyon
Alopecia usually begins with one or two small, roundish bald spots that appear on the scalp, or with diffuse shedding of hair. Some people may lose eyelashes in one area of the eyelid or eyebrow hair. In some people, the nails
develop stippling that looks as if a pin had made rows of tiny dents; in rare cases, the nails become severely distorted. Some people may have coexisting vitiligo, a loss of pigment in patches of the skin (the pigment melanin is present in hair root bulbs) or regrowth of white hair.
Some women develop only a few bare patches that regrow hair within a year. In others, extensive patchy loss occurs. When all scalp hair is lost, the condition is referred to as
alopecia totalis
; when hair is lost from the entire scalp and body, it’s called alopecia universalis. (This does not cause scarring, which can occur in lupus.)
Alopecia areata does not appear to be influenced by hormones. “A lot of my patients say they get worse in the spring or the fall; there’s a 30 percent incidence of allergy and atopy in alopecia areata patients. So it’s possible that they’re allergic and the pollens in spring or fall set the reaction,” says Dr. Duvic.
Some women may have alopecia areata and not even know it because hair loss occurs in the back of the scalp. In some cases, hairdressers are the ones who spot it.
While the coin-sized patches of baldness characteristic of alopecia areata are the key symptom, a dermatologist will take a medical history, including when the problem began, if there was any associated life stress, what kind of medications are being taken, what the hormonal status is, any unusual diet, and whether there’s a family history of baldness.
A dermatologist will also examine the scalp carefully for any scarring caused by trauma, lupus, or a skin disorder, which can be confirmed with a scalp biopsy. In some cases, a few hairs will be examined under a microscope. If there’s a root bulb at the end of a strand, it indicates a telogen hair. Hair lost during the growth phase has a club-like shape on its root end and can indicate a reaction to medication, among other things. Blood tests may also be done to see whether a woman has thyroid disease, a hormonal imbalance, lupus, or anemia.
“You have to rule out fungal infection of the scalp, which is often localized like alopecia areata, and there may be broken-off hairs, called ‘exclamation point hairs.’ If you don’t see specific patches and there’s a generalized loss, you
look for an infection. However, generalized hair loss can also occur during telogen effluvium,” says Dr. Duvic. “Low iron, which can cause anemia as well as hair loss, may be a contributing factor in some patients. There’s about a 30 percent incidence of thyroid problems in adults with alopecia areata; it can precede it or develop after it.”
“A biopsy is the most definite way to make a diagnosis. You will see lymphocytes around the root bulb of the follicle,” she stresses.
The choice of treatment depends mainly on a woman’s age and the type of alopecia. Alopecia areata occurs in two forms: a mild patchy form where less than 50 percent of scalp hair is lost and an extensive form where greater than 90 percent of scalp hair is lost. These two forms of alopecia areata behave quite differently, and treatment depends on which form you have.
Current approved treatments do not affect the autoimmune process that underlies alopecia but are aimed at stimulating the hair follicle to grow hair again. Treatments need to be continued until the disease process turns itself off. Treatments are most effective in milder cases.
In cases of mild, patchy alopecia areata, multiple injections of cortisone are done in and around bald patches and repeated once a month. If new hair growth occurs, it’s usually visible within four weeks. Local cortisone injections do not prevent new patches from developing, but they do kill T cells locally. Other than the needle prick and a slight tingling afterward, there are few side effects. Occasionally, temporary depressions in the skin result from the local injections, but these dells usually fill in by themselves. Topical, over-the-counter steroids don’t work with alopecia areata.
A solution of 5 percent topical
minoxidil
applied twice daily to the scalp and eyebrows may help regrow hair. If scalp hair regrows completely, treatment
can be stopped. Over-the-counter, 2 percent topical minoxidil solution is not effective by itself in alopecia areata; response may improve if cortisone cream is applied 30 minutes after the minoxidil. Topical minoxidil does not lower blood pressure in people with normal blood pressure. Neither 2 percent nor 5 percent topical minoxidil solution is effective in treating women with 100 percent scalp hair loss.
“Some people respond beautifully to minoxidil. However, those people may have grown back hair anyway. Alopecia areata is a hard disease to evaluate because a lot of people regrow hair no matter what, and there’s no way to predict who will regrow hair,” says Dr. Duvic.
Topical minoxidil hasn’t been studied among pregnant women, although animal studies suggest it may cause problems during pregnancy. It’s also not known whether topical minoxidil passes into breast milk. Limited tests have been conducted among older adults (up to age 65), and it appears to work better in younger patients. People with low blood pressure need to be careful about using too much and over large areas because topical minoxidil is actually a form of a drug used to treat hypertension.
Anthralin
is a synthetic, tarlike substance that is used for psoriasis. It’s applied to bare patches once daily and washed off after 30 to 60 minutes. Anthralin can be combined with minoxidil for an increased effect.
“Anthralin irritates the scalp; it attracts other T cells and they kind of override the hair-specific autoimmune attack. And then probably the immune system tries to shut off that reaction and takes the alopecia away. That’s how we think it works,” explains Dr. Duvic.
If new hair growth occurs with anthralin, it will be visible in 8 to 12 weeks. Side effects include irritation and temporary brownish discoloration, which can be lessened by shortening treatment times. Care must be taken not to get anthralin in the eyes. Hands must be washed after applying.
Anthralin may be absorbed through the skin, but no studies of its effects on pregnancy, in either humans or animals, have been done, and it’s not known whether it can pass into breast milk. No data are available on whether anthralin works differently in older women.
Oral corticosteroids (such as prednisone) are sometimes prescribed when there is extensive scalp hair loss. “If someone is going completely bald really quickly, and it is her first episode of alopecia areata, we try systemic steroids. Because if you can cut it off before it becomes established, then you might make a difference,” says Dr. Duvic.
The main problem is that any regrown hair is likely to fall out when the cortisone pills are stopped. In addition, there are health risks, such as bone loss, high blood pressure, diabetes, ulcers, and cataracts (see
pages 42
to
43
).
Topical sensitizers are medications that, when applied to the scalp, provoke an allergic reaction that leads to itching, scaling, and eventually hair growth. Two topical sensitizers are used in alopecia areata:
squaric acid dibutyl ester (SADBE)
and
diphenylcyclopropenone (DPCP).
Approximately 40 percent of patients treated with topical immunotherapy regrow scalp hair after about six months.
30
However, the treatment must be continued to maintain hair regrowth.
Photochemotherapy combining the light-sensitive drug
psoralen
and UV light, used most commonly for psoriasis, can be used in alopecia areata. PUVA is usually given two to three times per week at a specialized center. However, when used for long periods, PUVA may increase your risk of developing skin cancer.
A synthetic DMARD approved for RA,
tofacitinib (Xeljanz),
which disrupts the signaling of cytokines called
Janus-associated kinases (JAK)
may hold promise as a treatment for alopecia areata.
Studies in 2010 revealed that signals from JAK-associated cytokines in hair follicles cause NK cells to attack the follicles.
22
“We found that a ‘danger
signal’ in the hair follicles of patients—not previously linked to alopecia areata—attracts the immune cells to the follicle and sparks the attack,” explained researcher Angela M. Christiano, PhD, professor in the Departments of Dermatology and of Genetics and Development at Columbia University Medical Center in New York.
31
Later experiments in mice with alopecia found that interrupting those signals with JAK inhibitors completely restored hair within three months. The research prompted small clinical trials in alopecia patients of tofacitinib and
ruxolitinib (Jakafi)
, another JAK inhibitor approved to treat blood disorders. Preliminary results, reported in 2014 in the journal
Nature Medicine
, show ruxolitinib produced complete hair regrowth within five months in three patients with moderate-to-severe alopecia.
21
Tofacitinib and ruxolitinib are oral medications taken twice a day. A cream formulation is also under investigation.
Women with extensive hair loss often opt for wigs. Some newer, well-made wigs of synthetic or human hair have special tiny suction caps that keep them firmly in place, even during active sports. Another option is special double-sided tape, which can be purchased in beauty supply outlets. Cosmetic tattooing can be done on the eyebrow area and along the eyelids for an eyeliner effect. Then again, some women are proudly showing off their bald heads, rejecting the notion that the only way a woman can be beautiful is with long, thick hair.
Vitiligo
is caused by an immune attack on melanocytes, the skin cells that produce melanin, the pigment that gives skin its color. The result is white patches of skin, which may enlarge and increase in number. In some cases the condition may stabilize and then start up again.
Vitiligo affects 1 to 2 percent of Americans, and while it’s less obvious in light-skinned people, it can be traumatic for African Americans and other women of color. Half of women with vitiligo develop the disorder between the ages of 10 and 30, and it may be genetic in some cases.
Vitiligo is also associated with other autoimmune disorders. As many as 30 percent of women with vitiligo may develop thyroid disease. Women with vitiligo also have an increased risk of
pernicious anemia
or
Addison’s disease
(see
page 228
).
People with vitiligo must protect their skin from the sun; without the protection of melanin the affected patches of skin can become seriously sunburned. Women must use sunscreen with a
sun protection factor (SPF)
of at least 30 on exposed skin year-round (there are special sunscreens, like 60 SPF
Total Block
, designed for people with extreme sun sensitivity and those at high risk of skin cancer). Long sleeves and pants and wide-brimmed hats should be worn during long periods spent outdoors. Sun-protective clothing, made from special fabric that blocks out UV light, should have a hang tag that gives its
ultraviolet protection factor (UPF)
value and detail the testing standards it has met.
There’s no cure for vitiligo, but there are treatments that help restore lost melanin. The mainstay of treatment is PUVA, which can effectively darken white skin patches, especially if vitiligo is extensive. If vitiligo patches are very limited, occasionally psoralen can be applied directly to the skin before ultraviolet A treatment. At least a year of twice-weekly PUVA treatments is needed to restore melanin production.
PUVA is 50 to 70 percent effective in restoring pigment to vitiligo patches on the face, trunk, upper arms, and legs. However, the hands and feet respond poorly to PUVA. PUVA is not approved for use in pregnant or nursing women (see
page 156
).
If patches are small, corticosteroid creams may help restore pigment. However, chronic use of steroids can result in thinning and atrophy of the skin.
According to the American Academy of Dermatology, topical treatments work best for people with darkly pigmented skin. They work best on the face and are least effective on the hands and feet.
The
Excimer laser
, a small, intensely focused UV laser, is now used to treat limited vitiligo (covering less than 30 percent of the body’s surface) and stable
vitiligo patches.
24
Laser therapy is more effective when used early in the disease. Localized lesions are treated twice weekly for an average of 24 to 48 sessions, so the treatment can be costly. Adding tacrolimus ointment to laser therapy may improve results.
1
. Scleroderma Foundation. What is scleroderma?
http://
www.scleroderma.org/
site/
PageNavigator/
patients_
whatis.html#.VWiX3M9Viko
.
2
. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis.
Arthritis Rheum
. 2013. doi:10.1002/art.38098.
3
. Kowal-Bielecka O, Landewé R, Avouac J. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
Ann Rheum Dis
. 2009;68:620–628. doi:10.1136/ard.2008.096677.
4
. Herrick AL, van den Hoogen F, Gabrielli C, et al. Modified-release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis.
Arthritis Rheum.
2011;63(3):775–782. doi:10.1002/art.30195.
5
. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
JAMA
. 2014;311(24):2490–2498. doi:10.1001/jama.2014.6368.
6
. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial.
Lancet
. 2011;378(9790):498–506.
7
. Skoro-Sajer N, Lang IM. Selexipag for the treatment of pulmonary arterial hypertension.
Expert Opin Pharmacother.
2014;15(3):429–436. doi:10.1517/14656566.2014.876007. Epub 2014 Jan 7.
8
. Hudson M, Russell Steele R, Canadian Scleroderma Research Group (CSRG), and Baron M. Update on indices of disease activity in systemic sclerosis.
Semin Arthritis Rheum.
2007;37:93–98.
9
. Muangchan C, Harding S, Khimda S, et al., Canadian Scleroderma Research Group. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Arthritis Care Res.
2012;64(9):1405–1414. doi:10.1002/acr.21716.
10
. Steen V. Pregnancy in scleroderma.
Rheum Dis Clin
. 2007;33(2):345–358.
http://
dx.doi.org/
10.1016/
j.rdc.2007.03.001
.
11
. Vinet E, Bernatsky S, Hudson M, Pineau CA, Baron M. Effect of menopause on the modified Rodnan skin score in systemic sclerosis.
Arthritis Res Ther.
2014;16:R130. doi:10.1186/ar4587.
12
. Fraenkel L, Zhang Y, Chaisson CE, et al. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women.
Ann Intern Med
. 1998;129(3):208–211. doi:10.7326/0003-4819-129-3-199808010-00009.
13
. Impens1 AJ, Rothman J, Schiopu1 E, et al. Sexual activity and functioning in female scleroderma patients.
Clin Exp Rheumatol
. 2009;27(suppl 54):S38–S43.
14
. Golpour M, Hamzeh Hosseini SM, Khademloo M, et al. Depression and anxiety disorders among patients with psoriasis: a hospital-based case-control study.
Dermatol Res Pract.
2012. doi:10.1155/2012/381905.
15
. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.
J Am Acad Dermatol.
2013;69(5):729–735. doi:10.1016/j.jaad.2013.07.023.
16
. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis.
J Am Acad Dermatol.
2008;58(5):851–864.
17
. Veale DJ, Fearon U. What makes psoriatic and rheumatoid arthritis so different?
Rheum Musculoskeletal Dis, RMD Open.
2015;1:e000025. doi:10.1136/rmdopen-2014-000025.
18
. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.
Ann Rheum Dis
. 2012;71(1):4–12. Epub 2011 Sep 27.
19
. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis.
Ann Rheum Dis.
2009;68:1387–1394.
20
. Eder L, Thavaneswaran A, Chandran V, Gladman DD. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
Ann Rheum Dis
. 2014; 73:1007.
21
. Cimzia (certolizumab pegol) Fact Sheet, 2015.
https://
www.psoriasis.org/
document.doc?
id=
2755
.
22
. Stelara (ustekinumab) Fact Sheet. 2013.
https://
www.psoriasis.org/
document.doc?
id=
661
.
23
. FDA approves Otezla to treat psoriatic arthritis. FDA Press Release, March 21, 2014.
http://
www.fda.gov/
NewsEvents/
Newsroom/
PressAnnouncements/
ucm390091.htm
.
24
. Mudigonda T, Dabade TS, Feldman SR. A review of protocols for 308 nm excimer laser phototherapy in psoriasis.
J Drugs Dermatol
. 2012;11(1):92–97.
25
. Soriatane Prescribing information.
http://
www.drugs.com/
pro/
soriatane.html
.
26
. FDA, Alefacept package insert.
http://
www.fda.gov/
downloads/
Drugs/
DevelopmentApprovalProcess/
HowDrugsareDevelopedandApproved/
ApprovalApplications/
TherapeuticBiologicApplications/
ucm086009.pdf
.
27
. Stelara (ustinumab) Fact Sheet.
https://
www.psoriasis.org/
document.doc?
id=
661
.
28
. Xing L, Zhenpeng Dai Z, Ali Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Nat Med.
2014. Advance online publication. doi:10.1038/nm.3645.
29
. Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.
Nature.
2010;466(7302):113–117. doi:10.1038/nature09114.
30
. Singh G, Lavanya MS. Topical immunotherapy in alopecia areata.
Int J Trichology.
2010;2(1):36–39. doi:10.4103/0974-7753.66911.
31
. FDA-approved drug restores hair in patients with alopecia areata. Columbia University Medical Center press release, August 17, 2014.